NEW YORK (GenomeWeb News) – Vermillion and Accelerate Diagnostics saw their share prices more than double during the first six months of 2013, pacing the GenomeWeb Daily News Index for the first half of the year.

Overall, the index was up nearly 17 percent from the end of 2012, beating the Dow Jones Industrial Average (+14 percent) and the Nasdaq Composite (+13 percent), but trailing the Nasdaq Biotech Index (+27 percent).

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.